The inter-relationships shared by diabetes and obesity are compelling Novo Nordisk AS to trial novel new drugs for treating people who are abnormally overweight even though commercial prospects for such therapies are unclear.
Novo Nordisk Targets 'Obesity Disease Market' Despite Commercial Doubts
Novo Nordisk is targeting obesity as a key disease market, but its CEO says global alliances are needed in future to help fight the global pandemic, including the food industry.
